NASDAQ: POMPomdoctor Ltd Stock
$0.10-0.01 (-9.09%)
Updated Jun 12, 2026
POM Price
$0.10
Fair Value Price
N/A
Market Cap
$14.19M
52 Week Low
$0.07
52 Week High
$6.43
P/E
-0.19x
P/B
-0.21x
P/S
0.3x
PEG
N/A
Dividend Yield
N/A
Revenue
$58.81M
Earnings
-$18.60M
Gross Margin
13.1%
Operating Margin
-29.52%
Profit Margin
-53.2%
Debt to Equity
-1.3
Operating Cash Flow
-$21M
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
POM Overview
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine POM's potential to beat the market
- POM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical Retailer
Industry Rating
D
POM
RankedUnranked of 4
RankedUnranked of 4
Be the first to know about important POM news, forecast changes, insider trades & much more!
POM News
Overview
Due Diligence Score
–
Industry Average (19)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how POM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
POM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
POM is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
POM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more POM due diligence checks available for Premium users.
Valuation
POM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.19x
Industry
-3.51x
Market
14.15x
POM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.21x
Industry
41.09x
POM's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
POM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
POM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$15.3M
Liabilities
$83.6M
Debt to equity
-1.3
POM's short-term liabilities ($32.08M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
POM's long-term liabilities ($54.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
POM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
POM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
POM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
POM vs Pharmaceutical Retailer Stocks
Pomdoctor Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.